Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021
Pulse Biosciences, Inc. (Nasdaq: PLSE) will report financial results for Q4 and full year 2020 after market close on February 22, 2021. A conference call is scheduled for 1:30 PM PT, allowing investors to hear management discuss the results. The company is known for its innovative Nano-Pulse Stimulation™ (NPS™) technology, which powers its CellFX® System, aimed at improving dermatologic outcomes while sparing non-cellular tissue. This system represents a multi-application platform with a utilization-based revenue model.
- The upcoming financial results may show positive metrics driven by the demand for CellFX System.
- The CellFX System provides a unique treatment option for dermatologic conditions, potentially increasing market share.
- None
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year 2020 after market close on Monday, February 22, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT.
Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.
To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005120/en/
FAQ
When will Pulse Biosciences report its financial results for 2020?
What time is the conference call for Pulse Biosciences regarding financial results?
How can investors listen to Pulse Biosciences' conference call?
What technology does Pulse Biosciences utilize in its products?
